Blue KC now covers Wegovy for members diagnosed with MASH
Last fall, the FDA approved injectable Wegovy for the treatment of MASH (Metabolic Dysfunction–Associated Steatohepatitis), a form of fatty liver disease. Importantly, this new indication does not require a diagnosis of obesity, which sets it apart from other recent nonweight-loss-specific indications (such as obstructive sleep apnea and cardiovascular risk reduction) for this medication class.
With this approval, Blue KC now provides coverage for injectable Wegovy for members diagnosed with MASH, if medical necessity criteria are met. Prior authorization is required, and if approved, Wegovy will be covered at the preferred brand cost share.
Was this helpful?
Thanks for your feedback!
